MedTrace Logo

Concentration Effect of Local Anesthetics on Femoral Nerve Block Efficiency

NCT03623230 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2019-07-10

No results posted yet for this study

Summary

US-guided femoral nerve block is used effectively in post-operative pain management in the surgical treatment of the lower extremity. However, the volume and concentration of the local anesthetic drug to be administered remains controversial. In this prospective, randomized, double-blinded study, patients who underwent unilateral primary total knee arthroplasty and successfully performed spinal anesthesia with standard method and dosage, will be selected for US-guided femoral nerve block after the operation. Patients will be divided into three groups with simple randomization. The First group will be determined as the control group (GCont) and only dressing will be applied to the patients. For second group(G125), 0,125% 20 ml local anesthetic and for the third group (G25), 0,25% 10 ml local anesthetic will be administered to the femoral nerve without changing the drug dose (25 mg bupivacaine). Whether there is a difference between post-op analgesia durations, motor block formation, mobilization time and 90° flexion time between the groups will be investigated.

Conditions

  • Anesthesia, Conduction
  • Arthroplasty, Replacement, Knee
  • Pain, Postoperative
  • Anesthesia and Analgesia

Interventions

PROCEDURE

Ultrasound Guided Femoral Nerve Block

Femoral nerve block will be applied post-operatively with guidance of USG and nerve stimulator

OTHER

Dressing

Only dressing will be applied to related area to protect blindness between groups

DRUG

Bupivacaine 0.25% Injectable Solution

Perineural Injection

DRUG

Bupivacaine 0.125% Injectable Solution

Perineural Injection

Sponsors & Collaborators

  • Bozyaka Training and Research Hospital

    lead OTHER

Principal Investigators

  • Zeki T TEKGUL, Associate Professor · Izmir Bozyaka Training and Research Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-10
Primary Completion
2018-12-12
Completion
2019-02-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03623230 on ClinicalTrials.gov